BridgeBio
Jul 06, 2020
Importance: Many patients with systemic amyloidosis are underdiagnosed. Overall, 25% of patients with immunoglobulin light chain (AL) amyloidosis die within 6…
The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), a subcutaneous formulation of daratumumab, for use in combination with bortezomib,…
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food…
Sep 13, 2020
Systemic amyloidosis is a rare protein misfolding and deposition disorder leading to progressive organ failure. There are over 15 types of systemic amyloidosis,…
Join the Amyloidosis Support Groupsexternal link, opens in a new tab for a webinar on AL Light Chain Amyloidosis. Speakers will include Dr. Morie Gertzexternal link…
Feb 29, 2020
Light-chain (AL) amyloidosis is a systemic syndrome characterized by progressive organ dysfunction leading to organ failure and death. The heart is the most…
Jan 27, 2020
Background/Aims:
The present Bayesian network meta-analysis (NMA) was to compare the efficacy of different chemotherapies and autologous stem cell transplantation (…
Apr 29, 2020
Daratumumab is a human monoclonal antibody targeting CD38, an antigen uniformly expressed by plasma cells in multiple myeloma and light-chain amyloidosis (AL). We…
Mayo Clinic School of Continuous Professional Development
May 23, 2021
Hilton - Mayo Clinic Area, Rochester, MN, USA
Course Directors: Shaji Kumar, MDexternal…
AL amyloidosis patients often have queries about diet and nutrition - about what types of foods are best to eat or avoid, or if there are any special diets they…